Evidence map›Paper›PMID 27885618›Full record

ArticleEJNMMI research2016

Pre-clinical quantitative imaging and mouse-specific dosimetry for

Ana M Denis-Bacelar, Sarah E Cronin, Chiara Da Pieve, Rowena L Paul, Sue A Eccles, Terence J Spinks, Carol Box, Adrian Hall, Jane K Sosabowski, Gabriela Kramer-Marek and 1 more

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Internal radiation dosimetry of aEJNMMI research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ana M Denis-BacelarJoint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, SM2 5NG, United Kingdom. ana.denisbacelar@icr.ac.uk.
Sarah E CroninJoint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, SM2 5NG, United Kingdom.
Chiara Da PieveJoint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, SM2 5NG, United Kingdom.
Rowena L PaulJoint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, SM2 5NG, United Kingdom.
Sue A EcclesDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, United Kingdom.
Terence J SpinksJoint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, SM2 5NG, United Kingdom.
Carol BoxDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, United Kingdom.
Adrian HallRadiopharmacy Department, The Royal Marsden Hospital NHS Foundation Trust, London, SM2 5PT, United Kingdom.
Jane K SosabowskiCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, United Kingdom.
Gabriela Kramer-MarekDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, United Kingdom.
Glenn D FluxJoint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, SM2 5NG, United Kingdom.
Institute of Cancer Research · GBRoyal Marsden Hospital · GBRoyal Marsden NHS Foundation Trust · GBQueen Mary University of London · GB

Funding

Cancer Research UK 16464
6 · The paper itself

Abstract

backgroundAccurate quantification in molecular imaging is essential to improve the assessment of novel drugs and compare the radiobiological effects of therapeutic agents prior to in-human studies. The aim of this study was to investigate the challenges and feasibility of pre-clinical quantitative imaging and mouse-specific dosimetry of

resultsFor the sphere sizes investigated (volume 0.03-1.17 ml), the calibration factor varied by a factor of 3.7, whilst for the range of tumour masses in the mice (41-232 mg), the calibration factor changed by a factor of 2.5. Comparisons between the mice imaging and the biodistribution results showed a statistically significant correlation for the tumour activity (r = 0.999, P < 0.0001) and the tumour mass calculations (r = 0.977, P = 0.0008), whilst no correlation was found for the %IA/g (r = 0.521, P = 0.29). Median tumour-absorbed doses per injected activity of 52 cGy/MBq (range 36-69 cGy/MBq) and 649 cGy/MBq (range 441-950 cGy/MBq) were delivered by

conclusionsThis study demonstrates the need for multidisciplinary efforts to standardise imaging and dosimetry protocols in pre-clinical imaging. Accurate image quantification can improve the calculation of the activity, %IA/g and absorbed dose. Diagnostic imaging could be used to estimate the injected activities required for therapeutic studies, potentially reducing the number of animals used.

Indexed as

111InDosimetryHER2Image quantificationPartial volume effectPre-clinicalRadiolabelled antibodiesSPECT

Identifiers

PMID27885618
PMCPMC5122527
OpenAlexW2552311726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.